{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:24:27Z","timestamp":1786983867529,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anais Brasileiros de Dermatologia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.abd.2023.12.004","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T22:01:08Z","timestamp":1721340068000},"page":"840-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of secukinumab in psoriasis: five-year real life experience"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6041-6636","authenticated-orcid":false,"given":"Ersoy","family":"Acer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-1920","authenticated-orcid":false,"given":"Hilal Kaya","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8985-6224","authenticated-orcid":false,"given":"Esra","family":"A\u011fao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2269-4694","authenticated-orcid":false,"given":"Hatice","family":"Ba\u015ft\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6072-6466","authenticated-orcid":false,"given":"Muzaffer","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9116-2288","authenticated-orcid":false,"given":"Zeynep Nurhan","family":"Sara\u00e7o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.abd.2023.12.004_bib0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.abd.2023.12.004_bib0010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.abd.2023.12.004_bib0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","article-title":"Secukinumab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.abd.2023.12.004_bib0020","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2012 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.abd.2023.12.004_bib0025","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.12.004_bib0030","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.12.004_bib0035","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1080\/09546634.2020.1839009","article-title":"Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey","volume":"33","author":"Y\u0131ld\u0131r\u0131m","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2023.12.004_bib0040","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jaad.2019.02.062","article-title":"A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients","volume":"81","author":"Ortiz-Salvador","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.12.004_bib0045","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","article-title":"In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis","volume":"20","author":"Galluzzo","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.abd.2023.12.004_bib0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","article-title":"Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain","volume":"30","author":"Notario","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2023.12.004_bib0055","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/09546634.2019.1671577","article-title":"Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study","volume":"31","author":"Chiricozzi","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.abd.2023.12.004_bib0060","first-page":"125","article-title":"Secukinumab in psoriasis: a single-center experience","volume":"55","author":"A\u011fao\u011flu","year":"2021","journal-title":"Turkderm Turk Arch Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.12.004_bib0065","doi-asserted-by":"crossref","first-page":"e15685","DOI":"10.1111\/dth.15685","article-title":"The role of lifestyle and nutrition in psoriasis: current status of knowledge and interventions","volume":"35","author":"Musumeci","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2023.12.004_bib0070","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","article-title":"Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish nationwide cohort study","volume":"101","author":"Schwarz","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.abd.2023.12.004_bib0075","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.abd.2023.12.004_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of psoriasis and comorbid diseases: a narrative review","volume":"13","author":"Bu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.abd.2023.12.004_bib0085","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.abd.2023.12.004_bib0090","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","article-title":"Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis","volume":"31","author":"Pinter","year":"2020","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.abd.2023.12.004_bib0095","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/jdv.16180","article-title":"Real-world evidence of secukinumab in psoriasis treatment \u2013 a meta-analysis of 43 studies","volume":"34","author":"Augustin","year":"2020","journal-title":"J Eur Acad Dermat Venereol"},{"key":"10.1016\/j.abd.2023.12.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15794","article-title":"Should we be concerned about gastrointestinal-related adverse events in patients with plaque psoriasis receiving secukinumab therapy? A retrospective, real-life study","volume":"35","author":"Diotallevi","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.abd.2023.12.004_bib0105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.abd.2023.12.004_bib0110","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.abd.2023.12.004_bib0115","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1111\/ajd.13588","article-title":"Secukinumab and infectious adverse effects: a real-life experience of 63 psoriasis patients","volume":"62","author":"Ergun","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.abd.2023.12.004_bib0120","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1684\/ejd.2022.4263","article-title":"Safety and efficacy of secukinumab in psoriasis patients infected with hepatitis B virus: a retrospective study","volume":"32","author":"Qin","year":"2022","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.abd.2023.12.004_bib0125","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["Anais Brasileiros de Dermatologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624001405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0365059624001405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:00:51Z","timestamp":1747652451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0365059624001405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0365059624001405"],"URL":"https:\/\/doi.org\/10.1016\/j.abd.2023.12.004","relation":{},"ISSN":["0365-0596"],"issn-type":[{"value":"0365-0596","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of secukinumab in psoriasis: five-year real life experience","name":"articletitle","label":"Article Title"},{"value":"Anais Brasileiros de Dermatologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.abd.2023.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}